Figure 1. Treatment of NIH/3T3 cells with trichostatin A (TSA) increases the acetylation of histone H2B at Lys20 detected by PathScan® Acetyl-Histone H2B (Lys20) Sandwich ELISA Kit #7222. TSA treatment does not affect the level of histone H2B that is detected by Western analysis. NIH/3T3 cells (70-80% confluent) were treated for 16-18 hours with 0.4 µM TSA at 37oC. Absorbance readings at 450 nm are shown in the top figure while the corresponding Western blots using Histone H2B Antibody #2722 (left panel) or Acetyl-Histone H2B (Lys20) Antibody #2571 (right panel) are shown in the bottom figure.
Figure 2. The relationship between the protein concentration of lysates from HeLa cells, untreated or treated with TSA, and the absorbance at 450 nm. HeLa cells (70-80% confluent) were treated for 16-18 hours with 4.0 µM TSA at 37oC. Cells were lysed using Cell Lysis Buffer (10X) #9803.
The PathScan® Acetyl-Histone H2B (Lys20) Sandwich ELISA Kit is a solid phase sandwich enzyme-linked immunosorbent assay (ELISA) that detects endogenous levels of Histone H2B when acetylated at Lys20. A Histone H2B Mouse mAb has been coated onto the microwells. After incubation with cell lysates, histone H2B protein (acetylated and non-acetylated) is captured by the coated antibody. Following extensive washing, Acetyl-Histone H2B (Lys20) Rabbit Antibody is added to detect acetylated Lys20 on the histone H2B protein. Anti-rabbit IgG, HRP-linked antibody is then used to recognize the bound detection antibody. HRP substrate, TMB, is added to develop color. The magnitude of the absorbance for this developed color is proportional to the quantity of histone H2B acetylated at Lys20.
Antibodies in kit are custom formulations specific to kit.
CST's PathScan® Acetyl-Histone H2B (Lys20) Sandwich ELISA Kit detects endogenous levels of histone H2B when acetylated at Lys20. As shown in Figure 1 using the Acetyl-Histone H2B (Lys20) Sandwich ELISA Kit #7222, a high level of acetylation at Lys20 on histone H2B is detected in NIH/3T3 cells when treated with trichostatin A (TSA). The level of total histone H2B (acetylated and non-acetylated) remains unchanged as shown by western analysis (Figure 1). Similar results are obtained when COS and Jurkat cells are treated with TSA (data not shown).
This kit detects proteins from the indicated species, as determined through in-house testing, but may also detect homologous proteins from other species.
Modulation of chromatin structure plays an important role in the regulation of transcription in eukaryotes. The nucleosome, made up of DNA wound around eight core histone proteins (two each of H2A, H2B, H3, and H4), is the primary building block of chromatin (1). The amino-terminal tails of core histones undergo various post-translational modifications, including acetylation, phosphorylation, methylation, and ubiquitination (2-5). These modifications occur in response to various stimuli and have a direct effect on the accessibility of chromatin to transcription factors and, therefore, gene expression (6). In most species, histone H2B is primarily acetylated at Lys5, 12, 15, and 20 (4,7). Histone H3 is primarily acetylated at Lys9, 14, 18, 23, 27, and 56. Acetylation of H3 at Lys9 appears to have a dominant role in histone deposition and chromatin assembly in some organisms (2,3). Phosphorylation at Ser10, Ser28, and Thr11 of histone H3 is tightly correlated with chromosome condensation during both mitosis and meiosis (8-10). Phosphorylation at Thr3 of histone H3 is highly conserved among many species and is catalyzed by the kinase haspin. Immunostaining with phospho-specific antibodies in mammalian cells reveals mitotic phosphorylation at Thr3 of H3 in prophase and its dephosphorylation during anaphase (11).
Explore pathways + proteins related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.